Rhythm Pharmaceuticals announced preliminary unaudited net product revenues of $57 million for Q4 2025, marking an 11% increase from Q3 2025.
FY 2025 net product revenue reached approximately $194 million, a 50% increase from FY 2024.
US sales of IMCIVREE contributed significantly to the revenue, with 68% in Q4 and 69% in full-year 2025.
Revenue Growth
Q4 2025 saw an 11% increase over Q3, and FY 2025 showed a remarkable 50% growth compared to FY 2024.
Upcoming Milestones
Anticipated milestones include FDA approval for IMCIVREE in acquired hypothalamic obesity and topline data readouts from ongoing trials in 2026.
Product Expansion
Plans to launch IMCIVREE for acquired hypothalamic obesity in the US and evaluate new therapies for rare neuroendocrine diseases in 2026.
- The strong revenue growth reflects Rhythm Pharmaceuticals' successful execution and market penetration in rare neuroendocrine diseases.
- Upcoming milestones indicate a promising outlook for the company, with potential FDA approvals and new product developments.
- Financial results highlight the company's focus on sustainable growth and commitment to transforming patient lives in rare disease areas.
Rhythm Pharmaceuticals' robust financial performance and upcoming milestones position the company for continued success in the rare disease market.